TY - JOUR
T1 - Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer
T2 - supplementary results from the BIG 1-98 randomised trial
AU - Rasmussen, Birgitte B.
AU - Regan, Meredith M.
AU - Lykkesfeldt, Anne E.
AU - Dell'Orto, Patrizia
AU - Del Curto, Barbara
AU - Henriksen, Katrine L.
AU - Mastropasqua, Mauro G.
AU - Price, Karen N.
AU - Méry, Eliane
AU - Lacroix-Triki, Magali
AU - Braye, Stephen
AU - Altermatt, Hans J.
AU - Gelber, Richard D.
AU - Castiglione-Gertsch, Monica
AU - Goldhirsch, Aron
AU - Gusterson, Barry A.
AU - Thürlimann, Beat
AU - Coates, Alan S.
AU - Viale, Giuseppe
PY - 2008/1
Y1 - 2008/1
N2 - Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range
AB - Background: The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours. Methods: The BIG 1-98 trial consists of four treatment groups that compare 5 years of monotherapy with letrozole or tamoxifen, and sequential administration of one drug for 2 years followed by the other drug for 3 years. Our study includes data from the 4922 patients randomly assigned to the two monotherapy treatment groups (letrozole or tamoxifen for 5 years; 51 months median follow-up [range
UR - http://www.scopus.com/inward/record.url?scp=37549056583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37549056583&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(07)70386-8
DO - 10.1016/S1470-2045(07)70386-8
M3 - Article
C2 - 18083065
AN - SCOPUS:37549056583
VL - 9
SP - 23
EP - 28
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 1
ER -